- Home
- AMLX
as 04-02-2025 1:30pm EST
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 330.5M | IPO Year: | 2022 |
| Target Price: | $7.50 | AVG Volume (30 days): | 799.8K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $7.27 | Next Earning Date: | 03-04-2025 |
| Revenue: | $87,371,000 | Revenue Growth: | -77.06% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Mar 3 '25 | Sell | $3.17 | 4,595 | $14,549.15 | 3,196,652 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Mar 3 '25 | Sell | $3.12 | 1,611 | $5,022.29 | 133,310 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Mar 3 '25 | Sell | $3.15 | 4,595 | $14,483.44 | 3,196,648 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Feb 24 '25 | Sell | $3.15 | 4,169 | $13,144.86 | 133,310 | |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Feb 3 '25 | Sell | $3.47 | 11,851 | $41,107.56 | 3,196,652 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Feb 3 '25 | Sell | $3.49 | 3,678 | $12,839.16 | 133,310 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Feb 3 '25 | Sell | $3.47 | 11,855 | $41,103.66 | 3,196,648 | |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Jan 6 '25 | Sell | $4.05 | 7,471 | $30,232.15 | 3,196,652 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Jan 6 '25 | Sell | $4.04 | 7,471 | $30,201.52 | 3,196,648 |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
Business Wire
5 hours ago
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Insider Monkey
6 days ago
Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5?
Simply Wall St.
a month ago
March 2025's Top Penny Stocks To Watch
GuruFocus.com
a month ago
Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Business Wire
a month ago
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
GuruFocus.com
a month ago
Amylyx Pharmaceuticals Inc (AMLX) Q4 2024: Everything You Need To Know Ahead Of Earnings
Business Wire
a month ago
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
Business Wire
a month ago
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
Compare AMLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.